Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
27 févr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
16 févr. 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of...
Editas Medicine to Participate in Upcoming Investor Conferences
08 févr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor...
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
08 janv. 2018 09h00 HE
|
Editas Medicine, Inc.
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first...
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 08h57 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
11 déc. 2017 18h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas Medicine Announces Third Quarter 2017 Results and Update
07 nov. 2017 16h03 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30,...
Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
03 nov. 2017 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine to Participate in Investor Conferences in October
03 oct. 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
12 sept. 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history...